Sesen Bio, Inc. (SESN) financial statements (2020 and earlier)
Company profile
| Business Address |
245 FIRST STREET CAMBRIDGE, MA 02142 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 48 | 50 | 15 | 25 | 36 | 54 | ||
| Cash and cash equivalents | 48 | 50 | 15 | 25 | 36 | 54 | ||
| Other undisclosed current assets | 6 | 1 | 0 | 1 | 0 | 0 | ||
| Total current assets: | 54 | 52 | 15 | 26 | 36 | 54 | ||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 0 | 0 | 1 | 1 | 0 | 0 | ||
| Intangible assets, net (including goodwill) | 59 | 59 | 59 | 77 | 0 | |||
| Goodwill | 13 | 13 | 13 | 17 | ||||
| Intangible assets, net (excluding goodwill) | 46 | 46 | 46 | 61 | 0 | |||
| Restricted cash and investments | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other noncurrent assets | 0 | 0 | 0 | 0 | ||||
| Other undisclosed noncurrent assets | (0) | |||||||
| Total noncurrent assets: | 60 | 60 | 60 | 78 | 1 | 1 | ||
| TOTAL ASSETS: | 114 | 112 | 75 | 104 | 37 | 55 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 8 | 6 | 5 | 3 | 3 | 5 | ||
| Accounts payable | 2 | 1 | 1 | 2 | 1 | 2 | ||
| Accrued liabilities | 6 | 5 | 4 | 2 | 2 | 2 | ||
| Employee-related liabilities | 1 | |||||||
| Interest and dividends payable | 0 | |||||||
| Debt | 4 | 0 | ||||||
| Due to related parties | 0 | |||||||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | 1 | |||
| Other liabilities | 0 | |||||||
| Other undisclosed current liabilities | (1) | |||||||
| Total current liabilities: | 9 | 6 | 5 | 4 | 8 | 5 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 10 | 10 | ||||||
| Long-term debt, excluding current maturities | 10 | 10 | ||||||
| Liabilities, other than long-term debt | 133 | 49 | 40 | 61 | 0 | 3 | ||
| Deferred compensation liability, classified | 0 | |||||||
| Deferred tax liabilities, net | ✕ | 16 | ||||||
| Deferred income tax liabilities | 13 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other liabilities | 0 | 0 | 0 | |||||
| Business combination, contingent consideration, liability | 120 | 48 | 40 | 45 | ||||
| Derivative instruments and hedges, liabilities | 3 | |||||||
| Total noncurrent liabilities: | 133 | 49 | 40 | 61 | 10 | 13 | ||
| Total liabilities: | 141 | 55 | 45 | 65 | 18 | 18 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | (27) | 44 | 18 | 39 | 19 | 37 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 267 | 230 | 170 | 162 | 144 | 129 | ||
| Accumulated deficit | (294) | (186) | (152) | (123) | (125) | (92) | ||
| Total stockholders' equity: | (27) | 44 | 18 | 39 | 19 | 37 | ||
| Other undisclosed liabilities and equity | 13 | 13 | 0 | 0 | ||||
| TOTAL LIABILITIES AND EQUITY: | 114 | 112 | 75 | 104 | 37 | 55 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 2 | |||
| Revenue, net | ✕ | ✕ | 0 | 30 | 1 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (0) | ||||||
| Gross profit: | 0 | 0 | 0 | 2 | |||
| Operating expenses | (108) | (35) | (30) | (27) | (36) | (35) | |
| Other undisclosed operating income | 30 | 1 | 0 | ||||
| Operating income (loss): | (108) | (35) | (29) | 3 | (35) | (33) | |
| Nonoperating income (expense) | 1 | 1 | 0 | (1) | 2 | (1) | |
| Other nonoperating income (expense) | 1 | 1 | 0 | (1) | 3 | (1) | |
| Interest and debt expense | (0) | (0) | |||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 0 | ||||||
| Income (loss) from continuing operations before income taxes: | (108) | (34) | (29) | 2 | (33) | (35) | |
| Income tax expense | (0) | ||||||
| Net income (loss): | (108) | (34) | (29) | 2 | (33) | (35) | |
| Other undisclosed net income attributable to parent | 0 | ||||||
| Net income (loss) attributable to parent: | (108) | (34) | (29) | 2 | (33) | (34) | |
| Preferred stock dividends and other adjustments | (1) | ||||||
| Net income (loss) available to common stockholders, diluted: | (108) | (34) | (29) | 2 | (33) | (35) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (108) | (34) | (29) | 2 | (33) | (35) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (108) | (34) | (29) | 2 | (33) | (35) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.